Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

References

• Wolf Pérez A-M, Lorenzen N, Vendruscolo M, Sormanni P. Assessment of therapeutic antibody developability by combinations of in vitro and in silico methods. Methods Mol Biol. 2022;2313:57–11.
   PubMedGoogle Scholar
• Saxena V, Panicucci R, Joshi Y, Garad S. Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates. J Pharm Sci. 2009;98(6):1962–79. doi:10.1002/jps.21592.
   PubMed Web of Science ®Google Scholar
• Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104(6):1885–98. doi:10.1002/jps.24430.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64. doi:10.1080/19420862.2018.1553476.
   PubMed Web of Science ®Google Scholar
• Negron C, Fang J, McPherson MJ, Wb S Jr, McCluskey AJ. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment. MAbs. 2022;14(1):2080628. doi:10.1080/19420862.2022.2080628.
   PubMed Web of Science ®Google Scholar
• Khetan R, Curtis R, Deane CM, Hadsund JT, Kar U, Krawczyk K, Kuroda D, Robinson SA, Sormanni P, Tsumoto K, et al. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. MAbs. 2022;14(1):2020082. doi:10.1080/19420862.2021.2020082.
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61–66. doi:10.4161/mabs.3.1.13799.
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu C-P, Stouch BJ, Hurh E, Gibbs MA. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011;50(2):131–42. doi:10.2165/11537430-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Betts A, Keunecke A, van Steeg Tj, van der Graaf Ph, Avery LB, Jones H, Berkhout J, van Steeg TJ, van der Graaf PH. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcrn Tg32 transgenic mouse using a population-modeling approach. MAbs. 2018;10(5):751–64. doi:10.1080/19420862.2018.1462429.
   PubMed Web of Science ®Google Scholar
• Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today. 2007;12(23–24):1018–24. doi:10.1016/j.drudis.2007.10.002.
   PubMed Web of Science ®Google Scholar
• Danhof M, de Jongh J, De Lange ECM, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2007;47:357–400. doi:10.1146/annurev.pharmtox.47.120505.105154.
   PubMed Web of Science ®Google Scholar
• Davda JP, Hansen RJ. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs. 2010;2(5):576–88. doi:10.4161/mabs.2.5.12833.
   PubMed Web of Science ®Google Scholar
• Chen J, Eshghi ST, Bova GS, Li QK, Li X, Zhang H. Epithelium percentage estimation facilitates epithelial quantitative protein measurement in tissue specimens. Clin Proteomics. 2013;10(1). Internet. doi:10.1186/1559-0275-10-18.
   PubMedGoogle Scholar
• Munz M, Fellinger K, Hofmann T, Schmitt B, Gires O. Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM. Front Biosci. 2008;13(13):5195–201. doi:10.2741/3075.
   PubMedGoogle Scholar
• Liu H, Rhodes M, Wiest DL, Vignali DA. On the dynamics of TCR: cD3 complex cell surface expression and downmodulation. Immunity. 2000;13(5):665–75. doi:10.1016/S1074-7613(00)00066-2.
   PubMed Web of Science ®Google Scholar
• Hu L, Hansen RJ. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies. J Pharm Sci. 2013;102(9):2898–908. doi:10.1002/jps.23504.
   PubMed Web of Science ®Google Scholar
• Zou H, Banerjee P, Leung SSY, Yan X. Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges. Front Pharmacol. 2020;11:997. doi:10.3389/fphar.2020.00997.
   PubMed Web of Science ®Google Scholar
• Danhof M, de Lange Ecm, Della Pasqua OE, Ploeger BA, Voskuyl RA, Delange E. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008;29(4):186–91. doi:10.1016/j.tips.2008.01.007.
   PubMed Web of Science ®Google Scholar
• Ait-Oudhia S, Ovacik MA, Mager DE. Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs. 2017;9(1):15–28. doi:10.1080/19420862.2016.1238995.
   PubMed Web of Science ®Google Scholar
• Marcantonio DH, Matteson A, Presler M, Burke JM, Hagen DR, Hua F, Apgar JF. Early feasibility assessment: a method for accurately predicting biotherapeutic dosing to inform early drug discovery decisions. Front Pharmacol. 2022:13. Internet. doi:10.3389/fphar.2022.864768.
   Web of Science ®Google Scholar
• Tiwari A, Kasaian M, Heatherington AC, Jones HM, Hua F. A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies. MAbs. 2016;8(5):983–90. doi:10.1080/19420862.2016.1172151.
   PubMed Web of Science ®Google Scholar
• Dwivedi G, Fitz L, Hegen M, Martin SW, Harrold J, Heatherington A, Li C. A multiscale model of interleukin-6-mediated immune regulation in Crohn’s disease and its application in drug discovery and development. CPT: Pharmacometrics & Systems Pharmacology. 2014;3(1):e89. doi:10.1038/psp.2013.64.
   PubMedGoogle Scholar
• Kondic A, Bottino D, Harrold J, Kearns JD, Musante CJ, Odinecs A, Ramanujan S, Selimkhanov J, Schoeberl B. Navigating between right, wrong, and relevant: the use of mathematical modeling in preclinical decision making. Front Pharmacol. 2022;13:860881. doi:10.3389/fphar.2022.860881.
   PubMed Web of Science ®Google Scholar
• Oldenborg P-A. CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease. ISRN Hematol. 2013;2013:614619. doi:10.1155/2013/614619.
   PubMedGoogle Scholar
• Latham P, Kaltenbrunner O, Curling J, Levine H, Rathore A. Costing issues in the production of biopharmaceuticals. BioPharm Int [Internet]. 2004 [[accessed 2022 Nov 20];17(2): https://www.biopharminternational.com/view/costing-issues-production-biopharmaceuticals.
   Web of Science ®Google Scholar
• Contract Development and Manufacturing Costs During Clinical Development of a New Drug. 2013. Applied Clinical Trials Online [Internet]. [accessed 2022 Nov 22]. https://www.appliedclinicaltrialsonline.com/view/contract-development-and-manufacturing-costs-during-clinical-development-new-drug
   Google Scholar
• Bianconi E, Piovesan A, Facchin F, Beraudi A, Casadei R, Frabetti F, Vitale L, Pelleri MC, Tassani S, Piva F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40(6):463–71. doi:10.3109/03014460.2013.807878.
   PubMed Web of Science ®Google Scholar
• Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):1–14. doi:10.1371/journal.pbio.1002533.
   Web of Science ®Google Scholar
• Trepel F. Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr. 1974;52(11):511–15. doi:10.1007/BF01468720.
   PubMedGoogle Scholar
• Puro RJ, Bouchlaka MN, Hiebsch RR, Capoccia BJ, Donio MJ, Manning PT, Frazier WA, Karr RW, Pereira DS. Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding. Mol Cancer Ther. 2020;19(3):835–46. doi:10.1158/1535-7163.MCT-19-1079.
   PubMed Web of Science ®Google Scholar
• Martinez-Torres A-C, Quiney C, Attout T, Boullet H, Herbi L, Vela L, Barbier S, Chateau D, Chapiro E, Nguyen-Khac F, et al. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans. PLoS Med. 2015;12(3):e1001796. doi:10.1371/journal.pmed.1001796.
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662–67. doi:10.1073/pnas.1121623109.
   PubMed Web of Science ®Google Scholar
• Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle. 2009;8(3):505–06. doi:10.4161/cc.8.3.7608.
   PubMed Web of Science ®Google Scholar
• Brooke G, Holbrook JD, Brown MH, Barclay AN. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J Immunol. 2004;173(4):2562–70. doi:10.4049/jimmunol.173.4.2562.
   PubMed Web of Science ®Google Scholar
• Jalil AR, Andrechak JC, Discher DE. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function. Antib Ther. 2020;3(2):80–94. doi:10.1093/abt/tbaa006.
   PubMedGoogle Scholar
• Leclair P, Liu C-C, Monajemi M, Reid GS, Sly LM, Lim CJ. CD47-ligation induced cell death in T-acute lymphoblastic leukemia. Cell Death Dis. 2018;9(5):544. doi:10.1038/s41419-018-0601-2.
   PubMedGoogle Scholar
• Andrejeva G, Capoccia BJ, Hiebsch RR, Donio MJ, Darwech IM, Puro RJ, Pereira DS. Novel SIRPα antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells. J Immunol. 2021;206(4):712–21. doi:10.4049/jimmunol.2001019.
   PubMed Web of Science ®Google Scholar
• Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O’rourke T, Narayanan S, Papadopoulos K, et al. First-in-human, first-in-class phase i trial of the anti-CD47 antibody Hu5F9-G4 in patients with Advanced Cancers. J Clin Oncol. 2019;37(12):946–53. doi:10.1200/JCO.18.02018.
   PubMed Web of Science ®Google Scholar
• Kebenko M, Goebeler ME, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. 2018;Internet. doi:10.1080/2162402X.2018.1450710.
   PubMed Web of Science ®Google Scholar
• Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43(8):1129–43. doi:10.1016/j.molimm.2005.07.034.
   PubMed Web of Science ®Google Scholar
• García-Martínez E, Gil GL, Benito AC, González-Billalabeitia E, Conesa MAV, García García T, García-Garre E, Vicente V, Ayala de la Peña F. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488. doi:10.1186/s13058-014-0488-5.
   PubMed Web of Science ®Google Scholar
• Thibault G, Bardos P. Compared TCR and CD3 epsilon expression on alpha beta and gamma delta T cells. Evidence for the association of two TCR heterodimers with three CD3 epsilon chains in This information is current as the TCR/CD3 complex. J Immunol. 1995;154:3814–20. doi:10.4049/jimmunol.154.8.3814.
   PubMed Web of Science ®Google Scholar
• Mahadeva S, Wyatt JI, Howdle PD. Is a raised intraepithelial lymphocyte count with normal duodenal villous architecture clinically relevant? J Clin Pathol. 2002;55(6):424–28. doi:10.1136/jcp.55.6.424.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, et al. Target antigen density governs the efficacy of anti–CD20-CD28-CD3 ζ chimeric antigen receptor–modified effector CD8+ T Cells. Journal of Immunology. 2015;194(3):911–20. doi:10.4049/jimmunol.1402346.
   PubMed Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102–17. doi:10.1016/j.ymeth.2018.10.026.
   PubMed Web of Science ®Google Scholar
• Tiwari A, Abraham AK, Harrold JM, Zutshi A, Singh P. Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling. Aaps J. 2017;19(2):510–19. doi:10.1208/s12248-016-0004-1.
   PubMed Web of Science ®Google Scholar
• Singh AP, Krzyzanski W, Martin SW, Weber G, Betts A, Ahmad A, Abraham A, Zutshi A, Lin J, Singh P. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. Aaps J. 2015;17(2):389–99. doi:10.1208/s12248-014-9690-8.
   PubMed Web of Science ®Google Scholar
• Kapitanov GI, Chabot JR, Narula J, Roy M, Neubert H, Palandra J, Farrokhi V, Johnson JS, Webster R, Jones HM. A mechanistic site-of-action model: a tool for informing right target, right compound, and right dose for therapeutic antagonistic antibody programs. Frontiers in Bioinformatics. 2021;1:1. Internet. doi:10.3389/fbinf.2021.731340.
   Google Scholar
• Yu J, Karcher H, Feire AL, Lowe PJ. From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. Aaps J. 2011;13(2):169–78. doi:10.1208/s12248-011-9256-y.
   PubMed Web of Science ®Google Scholar
• Lemaire V, Bassen D, Reed M, Song R, Khalili S, Lien YTK, Huang L, Singh AP, Stamatelos S, Bottino D, et al. From cold to hot: changing perceptions and future opportunities for quantitative systems pharmacology modeling in cancer immunotherapy. Clin Pharmacol Ther [Internet]. 2022. doi:10.1002/cpt.2770.
   PubMed Web of Science ®Google Scholar
• Mizrahi O, Ish Shalom E, Baniyash M, Klieger Y. Quantitative flow cytometry: concerns and recommendations in clinic and research. Cytometry B Clin Cytom. 2018;94(2):211–18. doi:10.1002/cyto.b.21515.
   PubMed Web of Science ®Google Scholar
• Pan S, Aebersold R, Chen R, Rush J, Goodlett DR, McIntosh MW, Zhang J, Brentnall TA. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res. 2009;8(2):787–97. doi:10.1021/pr800538n.
   PubMed Web of Science ®Google Scholar
• Cid-Barrio L, Calderón-Celis F, Abásolo-Linares P, Fernández-Sánchez ML, Costa-Fernández JM, Encinar JR, Sanz-Medel A. Advances in absolute protein quantification and quantitative protein mapping using ICP-MS. Trends Analyt Chem. 2018;104:148–59. doi:10.1016/j.trac.2017.09.024.
   Web of Science ®Google Scholar